{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:43:03Z","timestamp":1790394183766,"version":"4.1.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.drudis.2025.104561","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:16:46Z","timestamp":1764202606000},"page":"104561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacogenomics and mutation informatics: correlation of NAT2 mutations and isoniazid acetylation rate"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7298-3355","authenticated-orcid":false,"given":"Saroj","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali M.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104561_b0005","series-title":"Global Tuberculosis Report 2024","author":"WHO","year":"2024"},{"key":"10.1016\/j.drudis.2025.104561_b0010","series-title":"End TB Strategy, WHO Report 2023","author":"WHO","year":"2023"},{"key":"10.1016\/j.drudis.2025.104561_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0283726","article-title":"NAT2 global landscape: genetic diversity and acetylation statuses from a systematic review","volume":"18","author":"Guti\u00e9rrez-Virgen","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104561_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1535447","article-title":"The role of isoniazid dosage and NAT2 gene polymorphism in the treatment of tuberculous meningitis","volume":"15","author":"Jian","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104561_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1332752","article-title":"Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships","volume":"15","author":"Ulanova","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2025.104561_b0030","doi-asserted-by":"crossref","first-page":"16146","DOI":"10.1074\/jbc.M109.005546","article-title":"Antibiotic resistance in Mycobacterium tuberculosis: peroxidase intermediate bypass causes poor isoniazid activation by the S315G mutant of M. tuberculosis catalase-peroxidase (KatG)","volume":"284","author":"Suarez","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2025.104561_b0035","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12866-025-03816-9","article-title":"Prevalence of katG and inhA mutations associated with isoniazid resistance in Mycobacterium tuberculosis clinical isolates in Cameroon","volume":"25","author":"Nono","year":"2025","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.drudis.2025.104561_b0040","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s13318-022-00764-x","article-title":"Time for isoniazid pharmacogenomic-guided therapy of tuberculosis based on NAT2 acetylation profiles in India","volume":"47","author":"Khan","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.drudis.2025.104561_b0045","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1093\/cid\/ciz1212","article-title":"Cost-effectiveness of a pharmacogenomic test for stratified isoniazid dosing in treatment of active tuberculosis","volume":"71","author":"Rens","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.drudis.2025.104561_b0050","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s13318-024-00910-7","article-title":"Precision medicine strategies to improve isoniazid therapy in patients with tuberculosis","volume":"49","author":"Thomas","year":"2024","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.drudis.2025.104561_b0055","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1164\/rccm.202103-0564OC","article-title":"A rapid pharmacogenomic assay to detect NAT2 polymorphisms and guide isoniazid dosing for tuberculosis treatment","volume":"204","author":"Verma","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.drudis.2025.104561_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.06.012","article-title":"Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein","volume":"27","author":"Verma","year":"2022","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2025.104561_b0065","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/10408347.2017.1281098","article-title":"Isoniazid: a review of characteristics, properties and analytical methods","volume":"47","author":"Fernandes","year":"2017","journal-title":"Crit Rev Anal Chem"},{"key":"10.1016\/j.drudis.2025.104561_b0070","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.tube.2019.04.012","article-title":"Pharmacokinetics of isoniazid: the good, the bad, and the alternatives","volume":"116S","author":"Erwin","year":"2019","journal-title":"Tuberculosis"},{"key":"10.1016\/j.drudis.2025.104561_b0075","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00228-022-03362-7","article-title":"Influence of N-acetyltransferase 2 (NAT2) genotype\/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models","volume":"78","author":"Thomas","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2025.104561_b0080","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/03602532.2014.984070","article-title":"Pharmacogenetics of isoniazid-induced hepatotoxicity","volume":"47","author":"Perwitasari","year":"2015","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.drudis.2025.104561_b0085","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13795","article-title":"Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: a systematic review","volume":"17","author":"Surarak","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.drudis.2025.104561_b0090","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2174\/1389200218666171031121905","article-title":"Isoniazid resistance and dosage as treatment for patients with tuberculosis","volume":"18","author":"Nagel","year":"2017","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.drudis.2025.104561_b0095","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/j.clinthera.2020.09.009","article-title":"A systematic review and meta-analysis of isoniazid pharmacokinetics in healthy volunteers and patients with tuberculosis","volume":"42","author":"Hong","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.drudis.2025.104561_b0100","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4046\/trd.2017.80.3.255","article-title":"The role of N-acetyl transferases on isoniazid resistance from Mycobacterium tuberculosis and human: an in silico approach","volume":"80","author":"Unissa","year":"2017","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"10.1016\/j.drudis.2025.104561_b0105","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/17512433.2023.2196401","article-title":"Parametric population pharmacokinetics of isoniazid: a systematic review","volume":"16","author":"Li","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.drudis.2025.104561_b0110","first-page":"1072","article-title":"Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin","volume":"133","author":"Sarma","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.drudis.2025.104561_b0115","article-title":"Population pharmacokinetics and pharmacodynamics of isoniazid and its metabolite acetylisoniazid in Chinese population","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2025.104561_b0120","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MGM2-0003-2013","article-title":"The molecular genetics of mycolic acid biosynthesis","volume":"2","author":"Pawe\u0141czyk","year":"2014","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.drudis.2025.104561_b0125","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021147","article-title":"Tuberculosis drug development: history and evolution of the mechanism-based paradigm","volume":"5","author":"Chakraborty","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.drudis.2025.104561_b0130","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.meegid.2016.09.004","article-title":"Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis","volume":"45","author":"Unissa","year":"2016","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.drudis.2025.104561_b0135","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jsb.2015.04.008","article-title":"Crystal structure of the enoyl-ACP reductase of Mycobacterium tuberculosis (InhA) in the apo-form and in complex with the active metabolite of isoniazid pre-formed by a biomimetic approach","volume":"190","author":"Chollet","year":"2015","journal-title":"J Struct Biol"},{"key":"10.1016\/j.drudis.2025.104561_b0140","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1126\/science.280.5369.1607","article-title":"Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid","volume":"280","author":"Mdluli","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.drudis.2025.104561_b0145","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1042\/bj20011628","article-title":"Mycolic acid biosynthesis and enzymic characterization of the beta-ketoacyl-ACP synthase A-condensing enzyme from Mycobacterium tuberculosis","volume":"364","author":"Kremer","year":"2002","journal-title":"Biochem J"},{"key":"10.1016\/j.drudis.2025.104561_b0150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.chembiol.2013.11.011","article-title":"Mycolic acids: structures, biosynthesis, and beyond","volume":"21","author":"Marrakchi","year":"2014","journal-title":"Chem Biol"},{"key":"10.1016\/j.drudis.2025.104561_b0155","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.8284673","article-title":"InhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis","volume":"263","author":"Banerjee","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.drudis.2025.104561_b0160","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02091-20","article-title":"Systematic review of mutations associated with isoniazid resistance points to continuing evolution and subsequent evasion of molecular detection, and potential for emergence of multidrug resistance in clinical strains of Mycobacterium tuberculosis","volume":"65","author":"Valafar","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2025.104561_b0165","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3390\/pathogens12081015","article-title":"Isoniazid and rifampicin resistance-conferring mutations in Mycobacterium tuberculosis isolates from South Africa","volume":"12","author":"Traor\u00e9","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.drudis.2025.104561_b0170","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1128\/AAC.00112-06","article-title":"Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis","volume":"50","author":"Hazb\u00f3n","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2025.104561_b0175","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/mmi.12476","article-title":"A silent mutation in mabA confers isoniazid resistance on Mycobacterium tuberculosis","volume":"91","author":"Ando","year":"2014","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.drudis.2025.104561_b0180","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/jat.3175","article-title":"Hepatotoxicity mechanisms of isoniazid: a mini-review","volume":"35","author":"Hassan","year":"2015","journal-title":"J Appl Toxicol"},{"key":"10.1016\/j.drudis.2025.104561_b0185","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/bcp.12885","article-title":"Mechanism of isoniazid-induced hepatotoxicity: then and now","volume":"81","author":"Metushi","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2025.104561_b0190","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1037814","article-title":"Mechanisms of isoniazid and rifampicin-induced liver injury and the effects of natural medicinal ingredients: a review","volume":"13","author":"Zhuang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2025.104561_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.155142","article-title":"Drug-induced liver injury and anti-hepatotoxic effect of herbal compounds: a metabolic mechanism perspective","volume":"122","author":"Rani","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.drudis.2025.104561_b0200","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/phpp.12659","article-title":"Pellagra a review exploring causes and mechanisms, including isoniazid-induced pellagra","volume":"37","author":"Prabhu","year":"2021","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.drudis.2025.104561_b0205","article-title":"Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis","volume":"36","author":"Maranchick","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"10.1016\/j.drudis.2025.104561_b0210","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4314\/ahs.v23i4.5","article-title":"Isoniazid hair drug levels among TB patients as a tool to monitor adherence, exposure, and TB treatment outcomes and its acceptability in a multicultural setting. A narrative review","volume":"23","author":"Muzanyi","year":"2023","journal-title":"Afr Health Sci"},{"key":"10.1016\/j.drudis.2025.104561_b0215","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.toxlet.2020.01.018","article-title":"Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin","volume":"322","author":"Combrink","year":"2020","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.drudis.2025.104561_b0220","doi-asserted-by":"crossref","first-page":"10197","DOI":"10.1038\/s41598-025-95050-6","article-title":"Association of NAT2 promoter hypermethylation with susceptibility to hepatotoxicity due to antituberculosis drugs and biomarker potential","volume":"15","author":"Jittikoon","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104561_b0225","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1164\/rccm.201910-1960OC","article-title":"Early bactericidal activity of different isoniazid doses for drug-resistant tuberculosis (INHindsight): a randomized, open-label clinical trial","volume":"201","author":"Dooley","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.drudis.2025.104561_b0230","series-title":"WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment \u2013 Drug-Resistant TB Treatment","author":"WHO","year":"2022"},{"key":"10.1016\/j.drudis.2025.104561_b0235","series-title":"Latent Tuberculosis Infection: A Guide for Primary Health Care Providers","author":"CDC","year":"2024"},{"key":"10.1016\/j.drudis.2025.104561_b0240","article-title":"The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India","volume":"31","author":"Bhargava","year":"2024","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"10.1016\/j.drudis.2025.104561_b0245","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3201\/eid3103.241473","article-title":"Evaluation of high-dose isoniazid in multidrug-resistant tuberculosis treatment","volume":"31","author":"Gerussi","year":"2025","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.drudis.2025.104561_b0250","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1331371","article-title":"The efficacy and safety of high-dose isoniazid-containing therapy for multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"14","author":"Zhou","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2025.104561_b0255","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/jac\/dkae057","article-title":"Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia","volume":"79","author":"Yunivita","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.drudis.2025.104561_b0260","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1441147","article-title":"Isoniazid-historical development, metabolism associated toxicity and a perspective on its pharmacological improvement","volume":"15","author":"Sankar","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2025.104561_b0265","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jsps.2020.04.003","article-title":"Determination of isoniazid acetylation patterns in tuberculosis patients receiving DOT therapy under the Revised National tuberculosis Control Program (RNTCP) in India","volume":"28","author":"Imam","year":"2020","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.drudis.2025.104561_b0270","series-title":"StatPearls","article-title":"Pharmacogenomics overview","author":"Guolin Wen","year":"2025"},{"key":"10.1016\/j.drudis.2025.104561_b0275","doi-asserted-by":"crossref","first-page":"e00456","DOI":"10.1128\/AAC.00456-20","article-title":"Acetylation of isoniazid is a novel mechanism of isoniazid resistance in Mycobacterium tuberculosis","volume":"65","author":"Arun","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2025.104561_b0280","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20180845","article-title":"Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence","volume":"39","author":"Khan","year":"2019","journal-title":"Biosci Rep"},{"key":"10.1016\/j.drudis.2025.104561_b0285","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FPC.0000000000000062","article-title":"PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2","volume":"24","author":"McDonagh","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.drudis.2025.104561_b0290","unstructured":"PharmVar Consortium. Human NAT2 Alleles (haplotypes). https:\/\/nat.mbg.duth.gr\/Human_NAT2_alleles.htm [Accessed November 24, 2025]."},{"key":"10.1016\/j.drudis.2025.104561_b0295","unstructured":"Pharmacogene Variation (PharmVar) Consortium. www.pharmvar.org\/gene\/NAT2 [Accessed November 24, 2025]."},{"key":"10.1016\/j.drudis.2025.104561_b0300","first-page":"29","article-title":"Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms","volume":"9","author":"Hein","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.drudis.2025.104561_b0305","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/carcin\/bgm085","article-title":"Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2","volume":"28","author":"Zang","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.drudis.2025.104561_b0310","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8765347","article-title":"Study on genotyping polymorphism and sequencing of N-acetyltransferase 2 (NAT2) among Al-Ahsa population","volume":"2020","author":"Zahra","year":"2020","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.drudis.2025.104561_b0315","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/01.fpc.0000236325.73186.2c","article-title":"Functional characterization of the A411T (L137F) and G364A (D122N) genetic polymorphisms in human N-acetyltransferase 2","volume":"17","author":"Zang","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.drudis.2025.104561_b0320","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12863-024-01286-y","article-title":"Pharmacogenomic insights into tuberculosis treatment shows the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis","volume":"25","author":"Mahajan","year":"2024","journal-title":"BMC Genom Data"},{"key":"10.1016\/j.drudis.2025.104561_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2025.149480","article-title":"Allele-specific detection of isoniazid metabolism modulating variants of N-acetyltransferase 2 enzyme and their frequencies in the Bangladeshi population","volume":"957","author":"Khan","year":"2025","journal-title":"Gene"},{"key":"10.1016\/j.drudis.2025.104561_b0330","doi-asserted-by":"crossref","first-page":"581","DOI":"10.4103\/0971-5916.187106","article-title":"N-acetyltransferase 2 (NAT2) gene polymorphism as a predisposing factor for phenytoin intoxication in tuberculous meningitis or tuberculoma patients having seizures - a pilot study","volume":"143","author":"Adole","year":"2016","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.drudis.2025.104561_b0335","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2478316","article-title":"Pharmacogenomic heterogeneity of N-acetyltransferase 2: a comprehensive analysis of real world data in Indian tuberculosis patients and from literature and database review","volume":"57","author":"Thomas","year":"2025","journal-title":"Ann Med"},{"key":"10.1016\/j.drudis.2025.104561_b0340","doi-asserted-by":"crossref","first-page":"e1987","DOI":"10.1002\/mgg3.1987","article-title":"NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients","volume":"10","author":"Jaramillo-Valverde","year":"2022","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.drudis.2025.104561_b0345","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2217\/pgs-2022-0022","article-title":"NAT2 polymorphism and clinical factors that increase antituberculosis drug-induced hepatotoxicity","volume":"23","author":"Mohamed Noor","year":"2022","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.drudis.2025.104561_b0350","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.3390\/ijms26083881","article-title":"NAT2 acetylation status predicts hepatotoxicity during antituberculosis therapy: cumulative risk analysis of a multiethnic cohort","volume":"26","author":"Schiuma","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104561_b0355","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/FPC.0000000000000544","article-title":"Differential distribution of NAT2 polymorphisms and NAT2 acetylator phenotypes among indigenous populations of the Brazilian Amazon","volume":"34","author":"Perini","year":"2024","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.drudis.2025.104561_b0360","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1164\/rccm.202309-1583OC","article-title":"A nanopore sequencing-based pharmacogenomic panel to personalize tuberculosis drug dosing","volume":"209","author":"Verma","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.drudis.2025.104561_b0365","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1006\/bbrc.2002.6414","article-title":"3D model of human arylamine N-acetyltransferase 2: structural basis of the slow acetylator phenotype of the R64Q variant and analysis of the active-site loop","volume":"291","author":"Rodrigues-Lima","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2025.104561_b0370","doi-asserted-by":"crossref","first-page":"30189","DOI":"10.1074\/jbc.M704138200","article-title":"Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases","volume":"282","author":"Wu","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2025.104561_b0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025801","article-title":"Effects of single nucleotide polymorphisms on human N-acetyltransferase 2 structure and dynamics by molecular dynamics simulation","volume":"6","author":"Rajasekaran","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104561_b0380","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cca.2021.04.017","article-title":"NAT2 polymorphisms associated with the development of hepatotoxicity after first-line tuberculosis treatment in Mexican patients: from genotype to molecular structure characterization","volume":"519","author":"Herrera-Rodulfo","year":"2021","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.drudis.2025.104561_b0385","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10822-013-9667-1","article-title":"Pyridones as NNRTIs against HIV-1 mutants: 3D-QSAR and protein informatics","volume":"27","author":"Debnath","year":"2013","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.drudis.2025.104561_b0390","unstructured":"NAT2 3-D protein structure (2PFR) retrieved from Protein Data Bank. (03\/07\/2025)."},{"key":"10.1016\/j.drudis.2025.104561_b0395","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.3390\/biom12121764","article-title":"Boosting the full potential of PyMOL with structural biology plugins","volume":"12","author":"Rosignoli","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2025.104561_b0400","unstructured":"MOE: The Molecular Operating Environment from Chemical Computing Group Inc. www.chemcomp.com [Accessed November 24, 2025]."},{"key":"10.1016\/j.drudis.2025.104561_b0405","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jmr.647","article-title":"IMGT standardized criteria for statistical analysis of immunoglobulin V-REGION amino acid properties","volume":"17","author":"Pommi\u00e9","year":"2004","journal-title":"J Mol Recognit"},{"key":"10.1016\/j.drudis.2025.104561_b0410","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0022-2836(82)90515-0","article-title":"A simple method for displaying the hydropathic character of a protein","volume":"157","author":"Kyte","year":"1982","journal-title":"J Mol Biol"},{"key":"10.1016\/j.drudis.2025.104561_b0415","series-title":"Lehninger Principles of Biochemistry","author":"Nelson","year":"2008"},{"key":"10.1016\/j.drudis.2025.104561_b0420","doi-asserted-by":"crossref","first-page":"W239","DOI":"10.1093\/nar\/gkl190","article-title":"CUPSAT: prediction of protein stability upon point mutations","volume":"34","author":"Parthiban","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2025.104561_b0425","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40262-024-01400-4","article-title":"Machine learning approach in dosage individualization of isoniazid for tuberculosis","volume":"63","author":"Tang","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.drudis.2025.104561_b0430","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jiph.2024.02.012","article-title":"Clinical utilization of artificial intelligence in predicting therapeutic efficacy in pulmonary tuberculosis","volume":"17","author":"Zhang","year":"2024","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.drudis.2025.104561_b0435","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/jcph.1931","article-title":"Isoniazid population pharmacokinetics and dose recommendation for Korean patients with tuberculosis based on target attainment analysis","volume":"61","author":"Cho","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2025.104561_b0440","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1186\/s12879-020-05256-4","article-title":"Machine learning reveals that Mycobacterium tuberculosis genotypes and anatomic disease site impacts drug resistance and disease transmission among patients with proven extra-pulmonary tuberculosis","volume":"20","author":"Sibandze","year":"2020","journal-title":"BMC Infect Dis"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625002740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625002740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:07:52Z","timestamp":1773335272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625002740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1359644625002740"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104561","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenomics and mutation informatics: correlation of NAT2 mutations and isoniazid acetylation rate","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104561","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104561"}}